3-24-2011: “Scientific trials have for decades documented the anti-cancer properties of cannabis and its constituents. Yet it took until this week for the website of the National Institute of Cancer, a component of the U.S. government’s National Institutes of Health, to finally acknowledged the herb’s therapeutic utility for patients living with disease or suffering from the adverse side-effects of cancer treatment.
In a newly added section to the website, entitled ‘Cannabis and Cannabinoids,’ the Institute states:
Cannabinoids may cause antitumor effects by various mechanisms, including induction of cell death, inhibition of cell growth, and inhibition of tumor angiogenesis and metastasis. Cannabinoids appear to kill tumor cells but do not affect their nontransformed counterparts and may even protect them from cell death.”
…The potential benefits of medicinal cannabis for people living with cancer include antiemetic effects, appetite stimulation, pain relief, and improved sleep. In the practice of integrative oncology, the health care provider may recommend medicinal cannabis not only for symptom management but also for its possible direct antitumor effect.”
It’s a stunning acknowledgment, given that the NIH is a branch of the very same government that presently maintains that the cannabis plant and all of its naturally-derived components have ‘no accepted medical use.’ Yet it also begs the question: Where has the National Institute of Cancer been all these years?
After all, the anti-tumor activity of cannabinoids were initially documented in 1975! That’s right; it’s taken 36 years for the Institute to get with the program.
Hopefully it won’t take them another 36 years to demand that the Feds finally assess whether these preclinical results are replicable in human trials.”
by Paul Armentano, NORML Deputy Director
“Cannabinoids exert antiproliferative effects in a wide range of tumoral cells, including hepatocellular carcinoma (HCC) cells. In this study, we examined whether the PPARγ-activated pathway contributed to the antitumor effect of two cannabinoids, Δ9-tetrahydrocannabinol (THC) and JWH-015, against HepG2 and HUH-7 HCC cells. Taken together, we demonstrate for the first time that the antiproliferative action of the cannabinoids THC and JWH-015 on HCC, in vitro and in vivo, are modulated by upregulation of PPARγ-dependent pathways.” 
